Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for Inflammatory Bowel Disease

 Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for Inflammatory Bowel Disease

Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for Inflammatory Bowel Disease

Shots:

  • BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the focus of identifying biomarkers using the XMarker platform
  • Boehringer Ingelheim gets an option to negotiate an exclusive right to biomarkers discovered under the collaboration.
  • The XMarker platform supports the phage therapy for IBD, BX002, via analysis of real-world metagenomic patient data. The BiomX will continue to advance the therapy in P-Ia study independently, which is expected to be initiated in Q3’20

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Downriver Gastroenterology, PC

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post